Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$5.96 USD
-0.21 (-3.40%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CADL 5.96 -0.21(-3.40%)
Will CADL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CADL
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Best Momentum Stocks to Buy for May 19th
New Strong Buy Stocks for May 19th
Other News for CADL
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference | CADL ...
Candel Therapeutics (CADL) Secures EMA Orphan Status for Pancreatic Cancer Treatment | CADL ...
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of ...
Candel Therapeutics receives EMA Orphan Designation for CAN-2409
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session